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Background: Foam generated bymanual agitation of liquid sclerosant with air or gas is routinely utilized to treat refluxing
veins. Although generally well tolerated, serious neurological events have been reported. The composition and properties
of the foam, including bubble size and gaseous components, may contribute to the potential for microcirculatory
obstruction and cerebral ischemia. We tested an ultra-low nitrogen polidocanol endovenous microfoam with controlled
bubble size and density and hypothesized that patients at risk due to the presence of middle cerebral artery (MCA) bubble
emboli during microfoam injection would not demonstrate evidence of clinical or subclinical cerebral infarction.
Methods: Patients with great saphenous vein incompetence were treated with ultra-low nitrogen (<0.8%) polidocanol
endovenous microfoam injected under ultrasound guidance. Patients with right-to-left shunt were included to evaluate
the safety of cerebral arterial bubbles. All patients withMCA emboli detected by transcranial Doppler during endovenous
microfoam ablation received intensive surveillance for microinfarction, including brain magnetic resonance imaging and
measurement of cardiac troponin-I.
Results: MCA bubble emboli were detected in 60 of 82 treated patients; 22 patients had no detectable emboli. Among
patients with MCA bubbles detected, 49 (82%) had <15 bubbles. No patients developed magnetic resonance imaging
abnormalities, neurological signs, or elevated cardiac troponin.
Conclusions: Patients treated with foamed liquid sclerosants are commonly exposed to cerebrovascular gas bubbles. In this
series of 60 high-risk patients with MCA bubble emboli during or after treatment with ultra-low nitrogen polidocanol
endovenous microfoam, there was no evidence of cerebral or cardiac microinfarction. The results of this study cannot be
generalized to foams compounded using bedside methodologies, since the composition of these foams is substantially
different. ( J Vasc Surg 2011;53:131-8.)Saphenous vein incompetence affects 20% to 25% of the
adult population.1 Nearly half of these patients report
symptoms impacting quality of life, and approximately 1%
of the adult population develops chronic ulceration due to
venous disease, resulting in significant medical costs and
loss of productivity.2 Intravenous sclerosing solutions such
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doi:10.1016/j.jvs.2010.06.179as polidocanol and sodium tetradecyl sulfate have been
utilized for decades to ablate veins by producing endothe-
lial injury, resulting in venous transformation to a fibrous
cord. Saphenous incompetence is commonly treated with
endovenous heat ablation (radiofrequency or laser), but
venous sclerosants are less invasive. Recent studies have
demonstrated that foamed sclerosants3 are twice as effica-
cious as liquid sclerosants in the treatment of larger veins
including the saphenous trunk veins.4,5 Foamed sclerosants
are also effective in treating complex venous malforma-
tions6 and incompetent veins associated with venous ul-
cers.7
Foamed sclerosants are generally created at the bedside
by agitating air (78% nitrogen) with liquid sclerosant.8
Variations on the technique include air-to-sclerosant ratios
from 2:1 to 8:1, use of different sclerosants in concentra-
tions from 0.5% to 3%, and the use of commercially avail-
able devices to assist the process. Consensus conferences in
2003 and 2006 produced guidelines on the creation and
clinical use of foamed sclerosants.9,10 These diverse foamed
sclerosants are widely used and have been relatively safe in a
series of 12,713 patients, half of whom were treated with
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reports of significant neurological events including major
stroke, seizures, and transient ischemic attacks in patients
subsequently demonstrated to have patent foramen
ovale.12,13 Gas was visualized in the vertebral and cerebral
arterial systems in two of these cases following injection of
modest volumes (4 and 10 mL) of foamed sclerosant. In
two recent reports, all patients injected with foamed scle-
rosants had gas bubbles visualized in the right heart cham-
bers using echocardiography, and some had bubbles in the
left heart.14,15 As patent foramen ovale is present in 25% to
30% of adults,16 a significant percentage of patients treated
with foamed sclerosants are exposed to gas bubbles in the
systemic arterial circulation.
The composition and properties of gas bubbles, includ-
ing their size and durability, contribute to their propensity
to obstruct the microvasculature17 and may influence the
tendency of certain foams to cause major neurological
events. We tested the hypothesis that an investigational
ultra-low nitrogen (0.8%) polidocanol endovenous mi-
crofoam designed to maintain specific microfoam charac-
teristics including bubble size, microfoam density, and
rapid gas absorption into blood18 would not cause clinical
or subclinical ischemia or infarction.
METHODS
Patients. Patients between 18 and 60 years of age with
saphenofemoral junction incompetence and GSV reflux
(1.0 second) were eligible if they also had clinically im-
portant manifestations of venous disease, including edema,
skin changes, or healed venous ulcers (CEAP 3, 4, or 5).
Excluded were patients with prior evidence of atheroscle-
rotic vascular disease, uncontrolled hypertension, diabetes
mellitus requiring insulin, hypercholesterolemia, venous
thromboembolism, body mass index 30, other major
medical disorders, small saphenous or deep venous incom-
petence (other than common femoral vein), clinically im-
portant echocardiographic abnormalities, medication with
oral contraceptives or anticoagulants, abnormal magnetic
resonance imaging (MRI) of the brain, and current smok-
ers. Initially each of five participating clinical practices
enrolled three to five patients without right-to-left (R-L)
shunt to ensure familiarity with study procedures and to
receive training from a physician-proctor on the technical
aspects of endovenous microfoam ablation; subsequent
patients were required to be positive for R-L shunt.
The protocol was approved by the Institutional Review
Boards of participating clinical practices, and all patients
provided written informed consent.
Study design. The study was conducted under an
investigational new drug (IND) application, and the study
sponsor developed the protocol in consultation with repre-
sentatives of the Food and Drug Administration. Because
this study was conducted under an IND, it was not possible
to include a nonapproved manually generated foam as
control.
Pretreatment evaluation for the presence of R-L shunt
was accomplished using transcranial Doppler (TCD) withinjection of contrast (8mL saline agitated with 1mL air and
1 mL blood).19 One contrast injection was performed at
rest and another while the patient performed the Valsalva
maneuver. Unilateral middle cerebral artery (MCA) bubble
counts were determined for 15 cardiac cycles to identify
patients with shunts that were likely to be intracardiac.
Patients testing Spencer grade 2 or greater (6 MCA
bubbles) at rest or following Valsalva were included.20
TCD surveillance was continued throughout the en-
dovenous microfoam ablation procedure, including during
application of compression bandaging and for an additional
10 minutes postprocedure until patients were standing.
After each of two periods of postprocedure ambulation,
TCDmonitoring was resumed such that each patient had a
minimum of 30 minutes postprocedure monitoring. All
treated patients were hospitalized for 24 hours following
the procedure and were monitored with continuous oxim-
etry, electrocardiograms 1 and 24 hours after the proce-
dure, and cardiac isoenzymes and troponin-I were mea-
sured every 8 hours.
Patients with periprocedural MCA emboli underwent
additional intensive surveillance including examination by a
neurologist, direct ophthalmoscopy and visual field testing
within 6 hours, and brain MRI within 24 hours. This
testing was repeated at 7 and 28 days, although the 7-day
MRI was discontinued from the protocol when it was
determined that this time point was capturing no additional
information. Any patient reporting visual or neurological
symptoms within 24 hours of treatment entered the inten-
sive neurological monitoring schedule regardless of
whether MCA emboli had been detected.
The initial determination of whether MCA bubble
emboli were present was made by personnel at the clinical
sites. The TCD recordings were subsequently reviewed by
an independent expert who counted all MCA emboli.
Therefore, it was possible for patients to be initially catego-
rized as negative by the clinical sites but subsequently
deemed positive by the TCD expert reviewer. Such patients
missed the 24-hour MRI and other early neurological
monitoring; in these cases, the clinical sites initiated inten-
sive surveillance procedures at the earliest opportunity.
Brain MRI was performed using a 1.5 T whole-body
system with a dedicated head or neurovascular coil, using a
sequence designed to maximize sensitivity to detect small
embolic lesions. Baseline MR sequences included sagittal
T1 localizer, axial diffusion-weighted image (b-value 
1000) with apparent diffusion coefficient map, axial T2,
axial T2*, and axial T2 fluid attenuated inversion recovery.
Patient recruitment continued until the accumulation of
50 patients with detectableMCAbubbles during or following
endovenous microfoam ablation. Clinical follow-up for all
patients after 7 and 28 days included duplex ultrasonogra-
phy of the treated limb to evaluate efficacy and perform a
detailed search for deep venous thrombosis.
Study organization. Patients were recruited by media
advertising. Those who successfully completed a study eli-
gibility questionnaire were referred to participating clinics
for informed consent and further screening. Study data
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also performed the statistical analysis. An independent re-
viewer adjudicated the MRI images as blinded pairs; each
posttreatment sequence matched with the corresponding
pretreatment sequence but was blinded to order and date.
A TCD expert without knowledge of each patient’s R-L
shunt status reviewed recordings made during endovenous
microfoam ablation and made the final determination re-
garding presence and number of embolic signals.
An independent Data and Safety Monitoring Board
reviewed progress every 6 months or more frequently and
was required to meet in an emergency session within 4 days
should any new MRI lesion be discovered by the indepen-
dent MRI reviewer.
Treatment. The investigational microfoam (Varisolve
polidocanol endovenous microfoam, BTG International
Ltd, W. Conshohocken, Pa) is formulated with a gas mix-
ture designed to maintain specific microfoam characteris-
tics while facilitating rapid gas absorption. A sterile con-
tainer system dispenses microfoam of reproducibly
consistent density, bubble size, and stability. The manufac-
turing process ensures that gas used to generate the micro-
foam has an extremely low nitrogen content (0.8%).
After the great saphenous vein (GSV), tributaries, and
perforators had been mapped, the GSV was cannulated just
above the knee under ultrasound guidance. TCDmonitor-
ing began 2 minutes prior to injection of microfoam.
Microfoam was injected under ultrasound guidance to
fill the proximal GSV from the point of cannulation to a
point 5 cm distal to the saphenofemoral junction. Addi-
tional microfoam was injected to fill the distal GSV and
varicose tributaries. The protocol allowed up to 20 mL of
microfoam to be delivered in one treatment session (one
patient received 24 mL).
The treated leg was wrapped in a short-stretch bandage
with compression pads over the treated venous segments. A
thigh-length 30 to 40 mm Hg compression stocking was
placed over the dressing. This compression system was
worn for 48 hours before removal. The stocking was worn
continuously for 2 weeks.
Statistical analysis. The study was designed to deter-
mine the frequency of new subclinical MRI abnormalities
suggestive of emboli or infarction in patients with MCA
bubbles detected after microfoam injection. For an ob-
served incidence of zero lesions in 50 patients, the upper
97.5% one-sided confidence limit for the true incidence rate
would be 7.11%, calculated using exact binomial probabil-
ities.
RESULTS
Between March 2007 and June 2008, 82 patients had
endovenous microfoam ablation of the GSV (Fig 1 and
Table I), 61 of whom had demonstrated R-L shunt.
The median volume of injected microfoam was 18 mL
(range, 6-24 mL), and following GSV cannulation, the
median duration of the procedure was 41 minutes (range,
14-114 minutes). Most MCA emboli were detected within
15 minutes of the microfoam injections (Fig 2). Of 82treated patients, 60 had one or more MCA bubble emboli
detected (Table II). Forty-nine patients (59.8%) had 15 or
fewer bubbles detected, and four (4.9%) had more than 50.
The maximum number of bubbles counted in any patient
was 382 (this latter patient also had a “curtain” of additional
emboli, which could not be individually counted). The num-
ber of MCA bubbles detected did not correlate with pretreat-
ment Spencer grade (Spearman non-parametric correlation
coefficient 0.3962).
MCA bubbles were detected during the microfoam
procedure in 54 (89%) of the 61 shunt-positive patients,
but 6 of 21 (29%) shunt-negative patients also had MCA
bubbles detected. The clinical site and the expert TCD
reviewer agreed on the TCD interpretation in 77 of 82
cases (94%).
All 60 patients with MCA bubble emboli had pretreat-
ment and at least one posttreatmentMRI scan. The blinded
independent assessor identified 10 patients with minor
pretreatment MRI abnormalities and all remained un-
changed in subsequent examinations. No lesions were evi-
dent in diffusion-weighted MRI sequences at any time
point in any patient. Three patients had no 24-hour MRI
examinations because MCA bubbles were detected only by
the expert TCD reviewer, but all had normal 28-day MRI
examinations. Two patients with normal 24-hour MRI
examinations declined the 28-day MRI follow-up.
There were no new neurological symptoms or findings
following treatment in any patient, whether or not MCA
emboli were detected. All visual field tests were normal or
unchanged, and no emboli were detected on fundoscopy.
One patient, for whom the expert TCD reviewer counted
three MCA emboli, described “twinkling lights” in her
peripheral vision appearing approximately 1 hour posttreat-
ment and lasting 20 seconds. Fundoscopy and visual field
testing conducted within minutes of the symptom were
normal, and the symptom did not recur. Because of the
brevity of the visual symptom and the lack of objective
signs, the investigator and consulting ophthalmologist did
not consider it clinically concerning. Markers of cardiac
ischemia were normal for all patients at all time points.
Other chemistry and hematology assessments remained
within normal limits.
At the day 28 follow-up visit, duplex ultrasound con-
firmed complete occlusion of the GSV in 71 of 81 patients
(88%) and elimination of saphenous reflux in 73 of 81
(90%).
Adverse events included pain or discomfort in the
treated limb (37 patients), expression of intravascular co-
agulum (11 patients), and ecchymosis (five patients). One
patient who could not be cannulated had extravascular
injection of 11 mL of microfoam. This patient experienced
no pain or adverse effect. One patient had a symptomatic
occlusive thrombus of a short section of popliteal vein,
associated with a tense knee effusion, which may have
contributed to the thrombosis. She was treated with 6
months of anticoagulation. Five other patients had asymp-
tomatic ultrasound evidence of thrombus involving the
deep veins (three with calf vein thrombi and two with
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junction involving the common femoral vein wall). Sclero-
sis of the GSV initiates intraluminal thrombosis of the
treated superficial vein, and in four additional patients,
there was convexity of the GSV luminal thrombus into the
lumen of the common femoral vein. In the absence of data
that these asymptomatic patients required anticoagulation,
most were conservatively managed with serial ultrasound
observation (five patients) or short periods of anticoagula-
tion (6-21 days; three patients); one patient was anticoag-
ulated for 90 days. All thrombi resolved, and none of these
patients had clinical sequelae or symptoms suggestive of
pulmonary embolism.
DISCUSSION
Despite widespread use of foamed sclerosants, the neu-
rological safety of physician-compounded foam sclerosant
has not been systematically studied. In an intravital micro-
scopic study in the rat, polidocanol foam compounded with
air following the Tessari technique8 caused arteriolar ob-
struction, whereas the investigational microfoam used in
the current clinical study did not obstruct the microvascu-
lature at much higher doses.17 Characteristics of the gas
bubbles appear to influence the propensity of foams to
cause microvascular occlusion and thus ischemic events
such as stroke, as well as more minor events such as tran-
sient visual disturbances and chest tightness.21
The current clinical study of the investigational micro-
foam was designed to investigate cerebrovascular safety
using diffusion-weighted MRI, the most sensitive tool
available for the detection of silent cerebral ischemia.22
Diffusion-weighted MRI is highly sensitive to edema for-
Table I. Characteristics of patients treated with
endovenous microfoam ablation (n  82)
Age (years)









Hispanic or Latino 2 (2.4)
CEAP clinical category, n (%)
CEAP 3 (edema) 72 (87.8)
CEAP 4 (skin changes without
ulceration) 6 (7.3)
CEAP 5 (skin changes with healed
ulceration) 4 (4.9)
Right-left shunt Spencer grade, n (%) At rest/with Valsalva
Grade 0 36 (43.9)/17 (20.7)
Grade 1 18 (22.0)/6 (7.3)
Grade 2 9 (11.0)/9 (11.0)
Grade 3 8 (9.8)/12 (14.6)
Grade 4 6 (7.3)/17 (20.7)
Grade 5 5 (6.1)/21 (25.6)mation as an early marker of injury (potentially reversible)while T2 and T2* detect permanent scarring, which, if
present, may not become apparent until at least 10 days
after the injury. Thus, with the MRI protocol used in this
study, minor injury could have been detected, and acute
and chronic lesions differentiated. Patients enrolled were
specifically selected to have a potential risk of microvascular
injury (screened for presence of right-to-left shunt). Each
of the 60 patients with detectable MCA emboli during
microfoam injection had multiple opportunities to experi-
ence an “event” since the bubbles were distributed system-
ically, and all vascular territories of the brain and other
organs were exposed to bubble emboli. The vascular terri-
tories most sensitive to ischemic damage were studied
intensively, including examination of the entire brain using
diffusion-weighted MRI, ophthalmoscopy and visual field
examination to detect ischemia of the retina or optic nerve,
and troponin-I, which is sensitive to silent myocardial in-
farction. These methodologies were selected to detect sub-
clinical injury that might not be apparent in a larger series
of patients less intensively studied.
The rate of deep vein thrombosis (one symptomatic
deep vein thrombosis, five asymptomatic thrombi) was
higher in this trial than in previous trials of endovenous
microfoam ablation (11 of 437 [2.5%] in a previous multi-
center study).18 In the current study, deep vein thrombosis
may have been increased due to postprocedure immobili-
zation for TCD monitoring and the required 24-hour
hospitalization. It is important to emphasize that all treated
patients in this study underwent careful posttreatment ul-
trasound examinations using high-resolution equipment,
resulting in detection of small asymptomatic thrombi of
uncertain clinical significance. Regardless of treatment mo-
dality, detection of deep vein thrombosis is clearly related
to whether and how exhaustively thrombi are prospectively
sought following the intervention.23-27
Because of concern regarding neurological events, con-
sensus guidelines suggest limiting the injected volume of
foamed sclerosants to 10mL or less.10 Despite the injection
in this study of relatively large volumes of investigational
microfoam (up to 24 mL), in most cases, only very low
numbers of MCA emboli were detected. EachMCA carries
approximately 3% of cardiac output; therefore, the bubbles
detected represent only a fraction of those injected. For
example, 30 bubbles counted in oneMCAwould equate to
1000 bubbles reaching the systemic arterial circulation,
which is 0.05% of the bubbles contained in a 20-mL dose of
proprietary microfoam (each mL contains approximately 1
million bubbles). Thus, it is clear that most injected bub-
bles never reach the systemic arterial circulation and are
either extinguished in the venous circulation (by absorp-
tion of gas into the blood) or filtered by the lung capillaries.
Most MCA bubbles were detected soon after injection
of microfoam; thus, if circulating bubbles posed a risk, this
should have been apparent within the first hour postproce-
dure. SinceMCAbubbles were detected in nearly one-third
of patients testing negative for R-L shunt, it is evident that
in clinical practice, prescreening patients for R-L shunt
prior to injection of foamed sclerosants would not be
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tinued for up to 60minutes followingmicrofoam injection,
MCA bubbles detected might have represented either in-
tra- or extracardiac shunting.
Since arterial bubble emboli cannot be avoided during
injection of foamed sclerosants, it is important that the
injected drug have characteristics consistent with clinical
safety. In this series of 60 intensively-studied high-risk
patients with cerebral arterial gas bubble embolization fol-
lowing saphenous ablation with a proprietary ultra-low
nitrogen endovenous microfoam, there were no clinically
important symptoms and no detectable cerebral or cardiac
injury. A larger series of unselected patients treated with the
proprietary ultra-low-nitrogen microfoam and followed for
clinical events will provide additional data to complement
the results of this series. The results of this study cannot be
Fig 2. Transcranial Doppler (TCD) bubbles per min
microfoam (all treated patients combined).
Table II. MCA bubble emboli during or after
endovenous microfoam ablation (expert TCD reviewer)
Patients with endovenous microfoam
ablation 82
Patients with MCA bubble emboli during
procedure 60 (73%)
Number of MCA bubble emboli in patients
with detectable bubbles (n60)
Mean  SD 21.8  62.14
Median 5.0
Range 1-382
Bubble count category during procedure
(categories corresponding to Spencer






MCA, Middle cerebral artery; TCD, transcranial Doppler.
*Smith KH, Spencer MP. Doppler indices of decompression sickness: Their
evaluation and use. Aerosp Med 1970;41:1396-400.extrapolated to other forms of foamed sclerosants sincefoams compounded using bedside methodologies differ in
bubble size and gas composition, properties that may con-
tribute to the potential for microcirculatory obstruction
and cerebral ischemia.
AUTHOR CONTRIBUTIONS
Conception and design: JER, DW
Analysis and interpretation: JDR, KG, CS, SH, JER, DW
Data collection: JDR, KG, CS, SH, JER, DW
Writing the article: JER, DW
Critical revision of the article: JDR, KG, CS, DW, SH
Final approval of the article: JDR, KG, CS, DW, SH, JER
Statistical analysis: JER, DW
Obtained funding: DW, JER
Overall responsibility: JDR
REFERENCES
1. Criqui MH, Jamosmos M, Fronek A, Denenberg JO, Langer RD,
Bergan J, et al. Chronic venous disease in an ethnically diverse popula-
tion. The San Diego Population Study. Amer J Epidemiol 2003;158:
448-56.
2. Phillips T, Stanton B, Provan A, Lew R. A study of the impact of leg
ulcers on quality of life: financial, social and psychologic implications.
J Am Acad Dermatol 1994;31:49-53.
3. Cabrera J, Cabrera J, Garcia-Olmedo MA. Treatment of varicose
greater saphenous vein with sclerosant in Microfoam form: long term
outcomes. Phlebology 2000;15:19-23.
4. Hamel-Desnos C, Desnos P, Wollmann JC, Ouvry P, Mako S, Allaert
FA. Evaluation of the efficacy of polidocanol in the form of foam
compared with liquid form in sclerotherapy of the greater saphenous
vein: initial results. Dermatol Surg 2003;29:1170-5.
5. Rabe E, Otto J, Schliephake D, Pannier F. Efficacy and safety of great
saphenous vein sclerotherapy using standardised polidocanol foam: a
randomised controlled multicentre clinical trial. Eur J Vasc Endovasc
Surg 2008;35:238-45.
6. Cabrera J, Cabrera J, Garcia-Olmedo MA, Redondo P. Treatment of
venous malformations with sclerosant in microfoam form. Arch Derma-
tol 2003;139:1409-16.
7. Cabrera J, Redondo P, Becerra A, Garrido C, Cabrera J, Garcia-Olmedo
MA, et al. Ultrasound-guided injection of polidocanol microfoam in the
following initial injection of polidocanol endovenousutemanagement of venous leg ulcers. Arch Dermatol 2004;140:667-73.
JOURNAL OF VASCULAR SURGERY
Volume 53, Number 1 Gloviczki 1378. Tessari L, Cavezzi A, Frullini A. Preliminary experience with a new
sclerosing foam in the treatment of varicose veins. Dermatol Surg
2001;27:58-60.
9. Breu FX, Guggenbichler S. European Consensus Meeting on Foam
Sclerotherapy, April 4-6, 2003, Tegernsee, Germany. Dermatol Surg
2004;30:709-17, discussion 717.
10. Breu FX, Guggenbichler S, Wollmann JC. Duplex ultrasound and
efficacy criteria in foam sclerotherapy from the 2nd European Consen-
sus Meeting on Foam Sclerotherapy 2006, Tegernsee, Germany. Vasa
2008;37:90-5.
11. Guex JJ, Allaert FA, Gillet JL, Chleir F. Immediate and midterm
complications of sclerotherapy: report of a prospective multicenter
registry of 12,173 sclerotherapy sessions. Dermatol Surg 2005;
31:123-8.
12. Bush RG, Derrick M, Manjoney D. Major neurological events follow-
ing foam sclerotherapy. Phlebology 2008;23:189-92.
13. ForleeMV, GroudenM,MooreDJ, Shanik G. Stroke after varicose vein
foam injection sclerotherapy. J Vasc Surg 2006;43:162-4.
14. Ceulen RPM, Sommer A, Vernooy K. Microembolism during foam
sclerotherapy of varicose veins. N Eng J Med 2008;358:1525-6.
15. Rush JE, Wright DDI. More on microembolism and foam sclerother-
apy. N Eng J Med 2008;359:656-7.
16. Hagen PT, Scholtz DG, Edwards WD. Incidence and size of patent
foramen ovale during the first 10 decades of life: an autopsy study of 965
normal hearts. Mayo Clinic Proceedings 1984;59:17-20.
17. Eckmann DM, Kobayashi S, Min L. Microvascular embolization fol-
lowing polidocanol microfoam sclerosant administration. Dermatol
Surg 2005;31:636-43.
18. Wright D, Gobin JP, Bradbury AW, Coleridge-Smith P, Spoelstra H,
Berridge D, et al. Varisolve polidocanol microfoam compared with
surgery or sclerotherapy in the kmanagement of varicose veins in the
presence of trunk vein incompetence: European randomized controlled
trial. Phlebology 2006;21:180-90.
19. Sastry S, Daly K, Chengodu T,McCollumC. Is transcranial Doppler for
the detection of venous-to-arterial circulation shunts reproducible?
Cerebrovasc Dis 2007;23:424-9.
20. Smith KH, Spencer MP. Doppler indices of decompression sickness:
their evaluation and use. Aerosp Med 1970;41:1396-400.
21. Morrison N, Neuhardt DL, Rogers CR, McEown J, Morrison T,
Johnson E, et al. Comparisons of side effects using air and carbon
dioxide foam for endovenous chemical ablation. J Vasc Surg 2008;47:
830-6.
22. Bendszus M, Koltzenburg M, Burger R, Warmuth-Metz M, Hofmann
E, Solymosi L. Silent embolism in diagnostic cerebral angiography and
neurointerventional procedures: a prospective study. Lancet 1999;354:
1595-7.
23. Keith LM, Smead WL. Saphenous vein stripping and its complications.
Surg Clin North Am 1983;63:1303-12.
24. Van Rij AM, Chai J, Hill GB, Christie RA. Incidence of deep vein
thrombosis after varicose vein surgery. Brit J Surg 2004;91:1582-5.
on side-effects of 12,173 sclerotherapy sessions, 6739 performed25. Hingorani AP, Ascher E, Markevich N, Schutzer RW, Kallakuri S, Hou
A, et al. Deep venous thrombosis after radiofrequency ablation of
greater saphenous vein: a word of caution. J Vasc Surg 2004;40:500-4.
26. Mozes G, Kalra M, Carmo M, Swenson L, Gloviczki P. Extension of
saphenous thrombus into the femoral vein: a potential complication of
new endovenous ablation techniques. J Vasc Surg 2005;41:130-5.
27. Manufacturer and User Facility Device Experience (MAUDE) Data-
base. Available at: http://www.accessdata.fda.gov/scripts/cdrh/
cfdocs/cfMAUDE/search.cfm. Accessed Dec 8, 2008.
Submitted May 21, 2009; accepted Jun 20, 2010.
APPENDIX
The following individuals participated in the conduct
of the trial:
Clinical Sites: Wake Forest University School of
Medicine (Winston-Salem NC): J. Regan, M. Bettmann,
B. Kouri, L. Patella, P. Tesch; Lake Washington Vascular
and Overlake Hospital (Bellevue, Wash): K. Gibson,
B. Ferris, D. Pepper, T. Fortney, A. Ebert, C. Leafdale,
H. Covert; University of Southern CaliforniaMedical Cen-
ter (Los Angeles, Calif): V. Rowe, F. Weaver, D. Hood,
C. Pappas, S. Parese; Duke University School of Medicine
(Durham, NC): C. Shortell, T. Williams, S. Finley; Univer-
sity of Pittsburgh-Shadyside (Pittsburgh, Pa): S. Hirsch,
E. Dillavou, J. Brimmeier, T. Richardson.
Data and Safety Monitoring Board: Carlos Kase,
MD (chair) and Ravin Davidoff, MD (Boston Medical
Center), Howard Rowley, MD (University of Wisconsin-
Madison), Mark Espeland, PhD (Wake Forest University
School of Medicine).
Study Proctors: Mark Isaacs, MD, John Mauriello,
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During the past decade, foam sclerotherapy has been widely
used around the world for treatment of varicose veins, for ablation
of the incompetent saphenous veins, for perforating veins, or for
treatment of venous malformations. Although liquid forms of the
two most frequently used sclerosing agents, sotradecol and poli-
docanol, are now approved by the Federal Drug Administration
(FDA), the use of foam has no FDA approval in the United States.
Two European consensus meetings concluded that foam sclero-
therapy was a safe, effective, and minimally invasive treatment of
varicose veins with a low rate of complications.1,2
Reported complications of foam sclerotherapy have been in-
deed rare.3 In a prospective multicenter study, Guex et al4 reportedwith foam. Forty-nine incidents (0.4%) occurred, 37 after admin-
istration of foam. There were 20 cases of transient visual distur-
bances; in 19 cases, foam or air block was used. One patient
developed femoral vein thrombosis. In a systematic review of data
of more than 9000 patients who underwent foam sclerotherapy,
the rate of serious adverse effects, including pulmonary embolism
and deep vein thrombosis, was less than 1%. The median rate of
visual disturbance was 1.4%, headache occurred in 4.2%, and
thrombophlebitis in 4.7%.
Concerns about the use of foam have been raised when Bush5
and other authors6,7 reported on cases of stroke after foam sclero-
therapy in patients who had a patent foramen ovale. Factors
believed to increase the risk of stroke included the use of air instead
